

Vopratelimab

Catalogue No.:abx831465

Vopratelimab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ICOS/CD278, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Vopratelimab is an IgG1 ICOS antibody. Studies have shown that vopratelimab can not only activate effector T cells, but also inhibit intratumoral regulatory T cells (Treg cells) that weaken the immune response.

Target:	ICOS/CD278
Clonality:	Monoclonal
Reactivity:	Human
Expression:	Recombinant
Tested Applications:	ELISA, WB
Host:	Human
Recommended dilutions:	: Optimal dilutions/concentrations should be determined by the end user.
Conjugation:	Unconjugated
lsotype:	IgG ₁ Kappa
Form:	Liquid
Purity:	> 95%
Purification:	Purified from cell culture supernatants by Protein A/G chromatography.
Storage:	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer:	0.01 M PBS. pH 7.4.
CAS Number:	2039148-04-2
Concentration:	Batch-dependent, typically between 0.5-2.0 mg/ml.
Note:	THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
v1.0.0	Abbexa LTD, Cambridge, UK · Phone: +44 (0) 1223 755950 · Fax: +44 (0) 1223 755951 Abbexa LLC, Houston, TX USA · Phone: +1 832 327 7413 Abbexa BV, Leiden, NL Website: www.abbexa.com · Email: info@abbexa.com